Your browser doesn't support javascript.
loading
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study.
Ravi, Vinod; Subramaniam, Aparna; Zheng, Jing; Amini, Behrang; Trinh, Van A; Joseph, Jocelyn; Mennel, Robert G; Bishop, Andrew J; Sturgis, Erich M; Goepfert, Ryan P; Yalamanchili, Sudha; Botello, Gilberto; Stephen, Bettzy; Piha-Paul, Sarina A; Patel, Anisha B; Lazar, Alexander J; Conley, Anthony P; Benjamin, Robert S; Patel, Shreyaskumar R; Futreal, Phillip A; Somaiah, Neeta; Naing, Aung.
Afiliação
  • Ravi V; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Subramaniam A; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Zheng J; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Amini B; Musculoskeletal Imaging Department, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Trinh VA; Department of Clinical Pharmacy Services, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Joseph J; Department of Clinical Pharmacy Services, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Mennel RG; Texas Oncology-Baylor Charles A. Sammons Center, Dallas, Texas, USA.
  • Bishop AJ; Radiation Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Sturgis EM; Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.
  • Goepfert RP; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yalamanchili S; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Botello G; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Patel AB; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Conley AP; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Benjamin RS; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Patel SR; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Futreal PA; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Somaiah N; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Naing A; Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cancer ; 128(18): 3383-3391, 2022 09 15.
Article em En | MEDLINE | ID: mdl-35792683
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemangiossarcoma Tipo de estudo: Etiology_studies / Observational_studies Limite: Humans Idioma: En Revista: Cancer Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemangiossarcoma Tipo de estudo: Etiology_studies / Observational_studies Limite: Humans Idioma: En Revista: Cancer Ano de publicação: 2022 Tipo de documento: Article